CEL SCI Corp (CVM) stock
CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$1.85+0.19 (+11.45%)
Close on Nov 17, 2026Market cap $32.54MP/E –Yield –
Cel Sci operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cel Sci's operating income for the twelve months ending Jun 30, 2026 was -$22.29M. For fiscal 2025 it was -$24.81M. The highest annual figure on record is -$12.02M in fiscal 2009.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$24.81M | – |
| FY2024 | Sep 30, 2024 | -$26.35M | – |
| FY2023 | Sep 30, 2023 | -$31.48M | – |
| FY2022 | Sep 30, 2022 | -$36.06M | – |
| FY2021 | Sep 30, 2021 | -$36.19M | – |
| FY2020 | Sep 30, 2020 | -$28.99M | – |
| FY2019 | Sep 30, 2019 | -$20.20M | – |
| FY2018 | Sep 30, 2018 | -$16.77M | – |
| FY2017 | Sep 30, 2017 | -$21.41M | – |
| FY2016 | Sep 30, 2016 | -$23.65M | – |
| FY2015 | Sep 30, 2015 | -$32.39M | – |
| FY2014 | Sep 30, 2014 | -$25.67M | – |
| FY2013 | Sep 30, 2013 | -$19.87M | – |
| FY2012 | Sep 30, 2012 | -$17.24M | – |
| FY2011 | Sep 30, 2011 | -$17.99M | – |
| FY2010 | Sep 30, 2010 | -$18.56M | – |
| FY2009 | Sep 30, 2009 | -$12.02M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$5.56M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$5.33M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$5.37M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$6.03M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$5.49M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$6.39M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$6.89M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$6.12M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$6.67M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$7.08M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$6.49M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$7.47M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$8.18M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$8.18M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$7.65M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$8.95M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$8.72M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$9.55M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$8.84M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$8.47M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$10.46M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$8.53M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$8.73M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$8.44M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$6.97M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$6.72M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$6.86M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$5.64M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$5.21M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$4.31M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$5.03M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$3.53M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$4.09M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$4.22M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$4.93M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$3.80M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$4.76M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$7.91M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$4.94M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$6.64M | – |
See a number that looks wrong?